Wolf M, Boyer-Neumann C, Parent F, Eschwege V, Jaillet H, Meyer D, Simonneau G
Service d'Hématologie biologique, Hôpital Antoine Béclère, Clamart, France.
Eur Respir J. 2000 Feb;15(2):395-9. doi: 10.1034/j.1399-3003.2000.15b28.x.
Thrombotic lesions are consistently observed in chronic thromboembolic pulmonary hypertension (CTEPH) and frequently found in primary pulmonary hypertension (PPH). It remains unknown, however, whether thrombosis is related to defects of the antithrombotic pathway or to previous vascular injury. This study therefore analysed the frequency of both hereditary and acquired thrombotic risk factors in CTEPH and PPH. One hundred and forty-seven consecutive patients with CTEPH investigated in the author's institution were compared to 99 consecutive patients with PPH. In 116 CTEPH patients and 83 PPH patients, phospholipid-dependent antibodies (antiphospholipid antibodies and lupus anticoagulant) were analysed by both immunological and clotting assays. In patients enrolled since 1994 (46 CTEPH and 64 PPH), hereditary thrombotic risk factors were also determined. Antithrombin, protein C and protein S activities were measured by functional assays. Mutations of factor V and factor II were identified by polymerase chain reaction. The prevalence of hereditary thrombotic risk factors was not increased in patients with either PPH or CTEPH. In contrast, a high frequency of phospholipid-dependent antibodies was observed in PPH (10%) and more notably in CTEPH (20%). Moreover, in PPH, antibodies were present only in low titre whereas in CTEPH, half of the patients with antiphospholipid antibodies had high titres. In addition, in CTEPH all but one of the patients with lupus anticoagulant also had antiphospholipid antibodies. The most striking finding of this study was the high prevalence of phospholipid-dependent antibodies but their clinical relevance appears to be different in primary pulmonary hypertension and chronic thromboembolic pulmonary hypertension. In primary pulmonary hypertension, these antibodies in low titre probably reflect endothelial dysfunction. In contrast, in chronic thromboembolic pulmonary hypertension the presence of antibodies in high titre associated with lupus anticoagulant, underlines the role of thrombosis in the pathogenesis of this condition.
在慢性血栓栓塞性肺动脉高压(CTEPH)中始终能观察到血栓形成病变,并且在原发性肺动脉高压(PPH)中也经常发现。然而,血栓形成是否与抗血栓途径缺陷或先前的血管损伤有关仍不清楚。因此,本研究分析了CTEPH和PPH中遗传性和获得性血栓形成危险因素的频率。将作者所在机构连续研究的147例CTEPH患者与99例连续的PPH患者进行比较。对116例CTEPH患者和83例PPH患者,通过免疫学和凝血试验分析了磷脂依赖性抗体(抗磷脂抗体和狼疮抗凝物)。对1994年以来入组的患者(46例CTEPH和64例PPH),还确定了遗传性血栓形成危险因素。通过功能试验测量抗凝血酶、蛋白C和蛋白S活性。通过聚合酶链反应鉴定因子V和因子II的突变。PPH或CTEPH患者中遗传性血栓形成危险因素的患病率并未增加。相反,在PPH中观察到磷脂依赖性抗体的高频率(10%),在CTEPH中更明显(20%)。此外,在PPH中,抗体仅以低滴度存在,而在CTEPH中,一半抗磷脂抗体患者具有高滴度。另外,在CTEPH中,除1例患者外,所有狼疮抗凝物患者也都有抗磷脂抗体。本研究最显著的发现是磷脂依赖性抗体的高患病率,但它们在原发性肺动脉高压和慢性血栓栓塞性肺动脉高压中的临床相关性似乎有所不同。在原发性肺动脉高压中,这些低滴度抗体可能反映内皮功能障碍。相反,在慢性血栓栓塞性肺动脉高压中,高滴度抗体与狼疮抗凝物的存在强调了血栓形成在该病发病机制中的作用。